This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital sold 1,059,375 shares of CG Oncology in Q4, an estimated $43.84 million trade based on quarterly average prices. The disclosure is a notable institutional sell that could add supply pressure and affect near-term liquidity/pricing for CG Oncology shares.

Analysis

Kynam Capital sold 1,059,375 shares of CG Oncology in Q4, an estimated $43.84 million trade based on quarterly average prices. The disclosure is a notable institutional sell that could add supply pressure and affect near-term liquidity/pricing for CG Oncology shares.